Unicycive Therapeutics Enters Into License Accord With Lotus Pharmaceutical for Renazorb in South Korea
12:16 PM EST, 02/02/2023 (MT Newswires) -- Unicycive Therapeutics (UNCY) said Thursday its entered into an exclusive license agreement with Lotus Pharmaceutical for the development and commercializati
H.C. Wainwright Sticks to Its Buy Rating for Unicycive Therapeutics (UNCY)
Unicycive Stock Rises on License Deal in Korea for Kidney Disorder Drug Renazorb
Unicycive Announces Exclusive License, Development Agreement With Lotus For Renazorb In Republic Of Korea
Develops Renazorb opportunity in new market for patients with hyperphosphatemiaAgreement includes upfront payment, royalties, and milestone payments
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersAkanda (NASDAQ:AKAN) stock increased by 28.2% to $0.36 during Thursday's after-market session. Akanda's trading volume hit 4.1 million shares by close, accounting for 474.8% of its average volu
Unicycive Therapeutics Announces Acceptance of Abstracts at NKF Meetings
Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation's Spring Clinical Meetings
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Sees Significant Growth in Short Interest
Unicycive Therapeutics, Inc. (NASDAQ:UNCY – Get Rating) was the recipient of a large increase in short interest in the month of December. As of December 30th, there was short interest totalling 259,0
12 Health Care Stocks Moving In Friday's After-Market Session
GainersLucira Health (NASDAQ:LHDX) shares rose 29.5% to $0.51 during Friday's after-market session. Lucira Health's trading volume hit 3.7 million shares by close, accounting for 93.6% of its average
Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023
LOS ALTOS, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that four
Loading...
No Stock Yet